Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
The Food and Drug Administration (FDA) is issuing new regulations requiring pediatric studies of certain new and marketed drug and biological products. Most drugs and biologics have not been adequately tested in the pediatric subpopulation. As a result, product labeling frequently fails to provide directions for safe and effective use in pediatric patients. This rule will partially address the lack of pediatric use information by requiring that manufacturers of certain products provide sufficient data and information to support directions for pediatric use for the claimed indications.
D001688:Biological Products / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010372:Pediatrics / Q000592:standards*; D011356:Product Labeling / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration
D001688:Biological Products